Clinical Trials Start for Stroke Drug Developed by Scripps Research Institute, USC, and ZZ Biotech

By zzbiotech | August 8, 2012

Experimental drug may extend window for effective stroke treatment LA JOLLA, CA, August 8, 2012 — Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC) and further developed by biotech company ZZ Biotech. The clinical…

ZZ Biotech Initiates Phase 1 Study with 3K3A-APC for the Treatment of Acute Ischemic Stroke

By zzbiotech | August 8, 2012

HOUSTON, Texas, August 8, 2012—ZZ Biotech, LLC today announced that it has commenced dosing healthy volunteers in a Phase 1 clinical study with 3K3A-APC, a recombinant variant of human activated protein C (APC), being developed for the treatment of acute ischemic stroke. The Phase 1 study is a randomized, double-blind, placebo-controlled, single-center trial that will…

Experimental Drug May Extend Therapeutic Window for Stroke

By zzbiotech | July 17, 2012

Clinical safety trials in humans to start this summer LOS ANGELES, July 17, 2012 — A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy. Clinical trials to test…